This Analyst Sees Nearly 500% Upside in Avanir Pharmaceuticals (AVNR)
Tweet
Share
E-mail
Get Alerts AVNR Hot Sheet
Price: $16.96 --0%
Rating Summary:
4 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 3 | New: 2
Rating Summary:
4 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 3 | New: 2
Join SI Premium – FREE
Shares of Avanir Pharmaceuticals (NASDAQ: AVNR) are down 16 percent since reporting fourth quarter numbers after the close on Monday, but according to one analyst shares should be higher... much higher.
In a note dated 12/13, Summer Street lifted its price target on the maker of Nuedexta from $10 to $11 while reiterating their Buy rating.
The firm noted 10,210 prescriptions were written for Nuedexta during the fourth quarter, a 99% increase over the third quarter. The treatment for pseudobulbar affect (PBA) and neuropathic pain (NP) is growing at a strong 3-4% week-over-week average pace in the fiscal first quarter of 2012. They see roughly 4,800 prescriptions in November. This would be up from 4,100 in October and just 2,746 in July.
The firm estimates that an annualized 1,200 total weekly prescriptions would cover the fixed expenses of the company's specialty retail and institutional care sales force.
The company also continues to work with payers to ensure reimbursement. "Beginning January 1, 2012, AVNR has agreements with three of the top five payers that manage prescription plans," the firm notes. The company expects 35% of patients will have unrestricted access to Nuedexta.
In the EU, Avanir's Marketing Authorization Application (MAA) filing was accepted on November 17 and decision is expected in June 2012 at the earliest.
The firm's $11 price target is based on a 25x multiple of their FY:15 EPS of $0.77/share discounted at 20%.
With shares of Avanir trading at $1.90 per share, the $11 price target represents 480% upside.
For an analyst ratings summary and ratings history on Avanir Pharmaceuticals click here. For more ratings news on Avanir Pharmaceuticals click here.
In a note dated 12/13, Summer Street lifted its price target on the maker of Nuedexta from $10 to $11 while reiterating their Buy rating.
The firm noted 10,210 prescriptions were written for Nuedexta during the fourth quarter, a 99% increase over the third quarter. The treatment for pseudobulbar affect (PBA) and neuropathic pain (NP) is growing at a strong 3-4% week-over-week average pace in the fiscal first quarter of 2012. They see roughly 4,800 prescriptions in November. This would be up from 4,100 in October and just 2,746 in July.
The firm estimates that an annualized 1,200 total weekly prescriptions would cover the fixed expenses of the company's specialty retail and institutional care sales force.
The company also continues to work with payers to ensure reimbursement. "Beginning January 1, 2012, AVNR has agreements with three of the top five payers that manage prescription plans," the firm notes. The company expects 35% of patients will have unrestricted access to Nuedexta.
In the EU, Avanir's Marketing Authorization Application (MAA) filing was accepted on November 17 and decision is expected in June 2012 at the earliest.
The firm's $11 price target is based on a 25x multiple of their FY:15 EPS of $0.77/share discounted at 20%.
With shares of Avanir trading at $1.90 per share, the $11 price target represents 480% upside.
For an analyst ratings summary and ratings history on Avanir Pharmaceuticals click here. For more ratings news on Avanir Pharmaceuticals click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sea Ltd. (SE) PT Raised to $85 at Jefferies; 'Solid Execution Across Different Segments'
- Oppenheimer Reiterates Outperform Rating on Electronic Arts (EA)
- Halliburton (HAL) PT Raised to $52 at Wolfe Research
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
